|Day Low/High||78.15 / 80.57|
|52 Wk Low/High||64.18 / 86.72|
But, says Jim Cramer, almost every winning stock he's ever mentioned is overvalued or has been overvalued before its run.
The largest U.S. corporations have improved their corporate governance in many key areas in recent years. But there is a lot of work to do.
Strong earnings and guidance lift markets. We drop a couple of names from the portfolio.
GlaxoSmithKline could be among the suitors for United Therapeutics, the Evening Standard reported.
A majority of the test subjects were migraine pain-free two hours after the drug was administered.
Earnings help boost markets as D.C. isn't counted on for much of anything. Portfolio action (it was a busy week) includes a new position and a downgrade.
The Big Six GOP leaders, including Ryan and Mnuchin, are abandoning their plan for a border adjustment tax.
Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.
Despite some concerns, we expect to see strong earnings for the company moving forward as its new products continue to pay off.
Investors digest earnings from Alphabet Inc and Eli Lilly & Co.
U.S. stock futures turn higher on Tuesday following earnings from Alphabet.
Europe looks to rebound into earnings season
Aratana Therapeutics and Kindred Biosciences are promising drug developers in the pet space.
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.